Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immunic Inc (NQ: IMUX ) 1.100 -0.040 (-3.48%) Streaming Delayed Price Updated: 10:00 AM EDT, Jul 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Immunic Inc Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day May 20, 2024 Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler discusses the importance of clinical trials in the biotech industry to mark Clinical Trials Day on May 20. Via TheNewswire.com Immunic chief medical officer discusses promising treatments to mark World IBD Day May 17, 2024 Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler discusses Inflammatory Bowel Disease (IBD) with Proactive's Stephen Gunnion to mark World IBD Day on May 19. Via TheNewswire.com Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day May 16, 2024 Immunic Inc (NASDAQ:IMUX) chief scientific officer Hella Kohlhof joined Proactive's Stephen Gunnion on International Celiac Day, in the middle of Celiac Disease Awareness Month, to discuss the disease... Via TheNewswire.com Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones May 09, 2024 Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the company's first-quarter achievements and upcoming milestones for its clinical pipeline of orally administered,... Via TheNewswire.com Topics Intellectual Property Exposures Intellectual Property Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal May 01, 2024 Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in... Via TheNewswire.com Immunic Inc set to bring relief with encouraging results May 16, 2023 Dr Daniel Vitt, CEO of Immunic Inc (NASDAQ:IMUX), discusses the company's encouraging first-quarter performance with Proactive. Via TheNewswire.com Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month March 21, 2024 Immunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr Andreas Muehler discusses the complexities of multiple sclerosis (MS) during an interview with Proactive's Stephen Gunnion to mark MS Awareness Month,... Via TheNewswire.com Immunic CSO hails "great" progress with MS program October 24, 2023 Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof speaks to Thomas Warner at the Proactive London after returning from MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS meeting. She shares some... Via TheNewswire.com Immunic "super excited" about latest PMS trial data October 11, 2023 Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced encouraging interim data from its phase II CALLIPER trial... Via TheNewswire.com Immunic CEO hails "great day" after completing IMU-838 phase 2 trial enrolment August 21, 2023 Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced the completion of the enrolment of its phase 2 CALLIPER trial... Via TheNewswire.com Immunic CEO says Q2 results "couldn't be better" August 07, 2023 Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive following the release of the Munich-based biotechnology company's second-quarter financial results and... Via TheNewswire.com Immunic Inc eyeing "big step" for multiple sclerosis patients July 25, 2023 Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt joined Thomas Warner from Proactive ahead of World Brain Day to provide an update on the biotechnology company's novel multiple sclerosis (MS)... Via TheNewswire.com Immunic IMU-856 trial data "clearly goes beyond" initial expectations May 04, 2023 Immunic Inc (NASDAQ:IMUX) CEO Dr. Daniel Vitt speaks to Thomas Warner from Proactive after releasing new clinical trial data for the biotechnology company's IMU-856 molecule, which is aimed at... Via TheNewswire.com Immunic gets a "positive surprise" from lead asset trial April 13, 2023 Immunic Inc (NASDAQ:IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838)... Via TheNewswire.com Immunic Inc. (NASDAQ: IMUX) Featured in Virtual Coverage of the 34th Annual Roth Conference March 11, 2022 Via Investor Brand Network Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
